Global Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Growth, Share, Size, Trends and Forecast (2022 - 2028)

• GlaxoSmithKline (GSK) and Pfizer Inc. announced a merger in July 2020 which is expected to be completed in 2022. The merger of the two companies is intended to create a global leader in the development and commercialisation of innovative treatments for patients with benign prostatic hyperplasia (BPH). The companies plan to use their combined expertise, capabilities, and resources to develop novel products and treatments for BPH, such as combination therapies, novel drug delivery systems, and innovative patient support services.

• Astellas Pharma Inc. and Takeda Pharmaceutical Company Limited announced a merger in October 2020 which is expected to be completed in 2023. This merger is intended to create a global leader in the development and commercialisation of innovative treatments for patients with benign prostatic hyperplasia (BPH). The companies plan to use their combined expertise, capabilities, and resources to develop novel products and treatments for BPH, such as combination therapies, novel drug delivery systems, and innovative patient support services.

The global benign prostatic hyperplasia (BPH) treatment devices and equipment market is segmented by type, encompassing drug therapies and medical devices. Drug treatments primarily involve alpha blockers, such as tamsulosin and doxazosin, and 5-alpha reductase inhibitors, including finasteride and dutasteride. Alpha blockers are often prescribed for their ability to relax the muscles in the prostate and bladder neck, while 5-alpha reductase inhibitors are favored for reducing prostate size. This diversification in drug options allows for tailored treatment plans based on patient-specific needs, driving the demand for pharmaceutical solutions in the BPH market.

In terms of products, the market offers a range of medical devices used in BPH management, including resectoscopes, radiofrequency ablation devices, urology lasers, prostatic stents, and implants. Resectoscopes and lasers are particularly popular in minimally invasive surgical procedures due to their precision and reduced recovery times. The increasing preference for minimally invasive techniques over traditional surgeries is boosting the adoption of advanced medical devices, with radiofrequency ablation and laser therapies gaining significant traction in both developed and emerging markets.

The end-user landscape includes hospitals, ambulatory surgical centers (ASCs), clinics, and home-based care. Hospitals and ASCs dominate the market due to the availability of skilled professionals and advanced infrastructure necessary for complex BPH procedures. However, the rising trend of outpatient and home-based care is contributing to the growth of portable and user-friendly devices. This shift is especially prominent in regions with aging populations, as patients seek less invasive treatments with shorter hospital stays and faster recovery periods.

Geographically, the market is segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. North America leads in market share due to its well-established healthcare system, high adoption of advanced technologies, and increasing awareness about BPH treatments. Europe closely follows, with a strong emphasis on minimally invasive solutions. Meanwhile, Asia Pacific is emerging as a lucrative market, driven by a growing geriatric population, rising healthcare expenditure, and increased awareness of BPH-related issues. The Middle East and Africa, along with Latin America, are also witnessing steady growth, although challenges such as limited access to advanced treatments in certain regions may hinder market expansion.

Global Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Segment Analysis

In this report, the Global Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market has been segmented by Type, Product, End-User, Procedure and Geography.

Global Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market, Segmentation by Type

The Global Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market has been segmented by Type into Drug- Alpha Blockers (Tamsulosin, Doxazosin), 5-Alpha Reductase Inhibitors (Finasteride, Dutasteride).

The global benign prostatic hyperplasia (BPH) treatment devices and equipment market is categorized by type into drug-based solutions. The primary category within this segmentation focuses on alpha blockers, which are commonly prescribed to relax the muscles in the prostate and bladder neck, thereby easing urinary flow. Notable alpha blockers in this segment include tamsulosin and doxazosin, which are widely used for their effectiveness in reducing BPH symptoms.

Another significant type within the market is 5-alpha reductase inhibitors. These drugs work by reducing the production of dihydrotestosterone (DHT), a hormone that contributes to prostate enlargement. Finasteride and dutasteride are the leading drugs in this category, often prescribed for their ability to shrink the prostate gland and slow the progression of BPH, particularly in patients with larger prostate sizes.

The segmentation of the market by drug type highlights the broad range of therapeutic approaches available for managing BPH. While alpha blockers provide rapid symptom relief, 5-alpha reductase inhibitors are typically utilized for long-term management. This diversity in treatment options allows healthcare providers to tailor therapies based on the severity of the condition and the patient’s overall health profile, contributing to the market's steady growth.

Global Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market, Segmentation by Product

The Global Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market has been segmented by Product Into Resectoscopes, Radiofrequency ablation device, Urology lasers, Prostatic Stents and Implants.

Resectoscopes are fundamental instruments used primarily in Transurethral Resection of the Prostate (TURP), a common surgical procedure for BPH. These devices allow urologists to visualize and remove excess prostate tissue through a minimally invasive approach, reducing urinary symptoms such as frequency and urgency. The demand for resectoscopes is driven by their essential role in treating moderate to severe cases of BPH and their ability to achieve effective tissue removal while minimizing patient discomfort and recovery time.

Radiofrequency ablation devices represent another significant segment in the BPH treatment market, offering a non-surgical option for patients seeking relief from urinary symptoms. These devices use radiofrequency energy to heat and shrink enlarged prostate tissue, improving urine flow without the need for invasive surgery. Radiofrequency ablation is favored for its outpatient feasibility and lower risk of complications compared to traditional surgical methods, appealing to both patients and healthcare providers seeking effective yet less invasive treatment options.

Urology lasers play a critical role in advanced BPH treatment strategies, particularly through techniques like Holmium and GreenLight laser therapies. These lasers provide precise and controlled energy delivery for tissue ablation and vaporization, allowing urologists to remove obstructive prostate tissue while minimizing damage to surrounding structures. Laser therapies are favored for their ability to achieve significant symptom relief with reduced bleeding and shorter recovery periods, making them increasingly popular among patients seeking faster recovery times and improved quality of life.

Prostatic stents and implants offer alternative solutions for managing BPH symptoms, particularly for patients who may not be suitable candidates for surgical or laser treatments. These devices provide mechanical support to keep the prostatic urethra open, thereby reducing urinary obstruction and improving urine flow. Prostatic stents and implants are designed to be minimally invasive and offer temporary relief, making them suitable for patients who require symptomatic relief while exploring long-term treatment options.

Global Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market, Segmentation by End-User

The Global Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market has been segmented by End-User into Hospitals, Ambulatory Surgical Centres (ASC), Clinics and Home.

Hospital constitute a significant segment in the BPH treatment market, equipped with advanced facilities and skilled medical professionals capable of performing a wide range of surgical and minimally invasive procedures. Hospitals are pivotal in treating moderate to severe cases of BPH, offering comprehensive care pathways that include diagnosis, treatment, and post-operative management. The demand for BPH treatment devices in hospitals is driven by the need for effective surgical tools, such as resectoscopes and urology lasers, which are essential for procedures like Transurethral Resection of the Prostate (TURP) and laser therapies.

Ambulatory Surgical Centers (ASCs) are emerging as a critical segment in the BPH treatment market, catering to patients who prefer outpatient procedures or less invasive treatment options. ASCs offer convenience, cost-effectiveness, and shorter recovery times compared to traditional hospital settings, making them increasingly popular for procedures like laser ablation and prostatic stent placements. These centers are equipped with specialized equipment and skilled staff to provide efficient and personalized care, meeting the growing demand for minimally invasive BPH treatments in a comfortable outpatient environment.

Clinics play a vital role in the continuum of care for BPH patients, offering diagnostic services, consultation, and outpatient treatments. Urology clinics, in particular, specialize in the management of urological conditions such as BPH, providing access to specialized equipment like ultrasound machines for diagnosis and monitoring, as well as treatment options such as transurethral procedures and laser therapies. Clinics are valued for their accessibility and patient-centered care approach, catering to individuals seeking regular check-ups, symptom management, and non-surgical treatment alternatives.

Home-based care represents a niche segment in the BPH treatment market, focusing on patient education, self-management, and the use of specialized devices for at-home symptom relief. While surgical interventions are typically performed in clinical settings, home-based care includes the provision of urinary catheters, medications, and portable devices like prostatic stents for temporary relief of BPH symptoms. This segment emphasizes patient empowerment and quality of life improvements, supporting ongoing management and monitoring of BPH symptoms in a familiar environment.

Global Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market, Segmentation by Procedure

The Global Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market has been segmented by Procedure into Transurethral Needle Ablation (TUNA), Transurethral Resection of Prostate (TURP), Transurethral Incision of Prostate (TUIP), Transurethral microwave thermotherapy (TUMT), Laser surgery and Others.

Transurethral Resection of the Prostate (TURP) is a cornerstone procedure in BPH treatment, utilizing resectoscopes equipped with cutting and coagulating electrodes to remove excess prostate tissue obstructing the urethra. TURP is favored for its effectiveness in relieving urinary symptoms and its long-standing history as a gold standard surgical treatment for BPH.

Laser surgeries, including techniques such as GreenLight laser therapy and Holmium laser enucleation of the prostate (HoLEP), offer advanced alternatives to traditional surgical methods. These procedures use laser energy to vaporize or enucleate prostate tissue, achieving precise tissue removal with reduced bleeding and shorter recovery times compared to TURP. Laser surgeries are increasingly preferred for their ability to provide effective symptom relief while minimizing surgical complications.

Transurethral Needle Ablation (TUNA) employs radiofrequency energy delivered through needles to thermally ablate prostate tissue, reducing obstruction and urinary symptoms. TUNA is valued for its minimally invasive nature and outpatient feasibility, making it suitable for patients seeking a less invasive treatment option with rapid recovery.

Transurethral Microwave Thermotherapy (TUMT) utilizes microwave energy to heat and destroy prostate tissue, improving urine flow and reducing BPH symptoms. TUMT procedures are performed using specialized equipment designed to deliver controlled thermal energy to the prostate gland, offering an outpatient treatment option with minimal recovery time.

Transurethral Incision of the Prostate (TUIP) involves making small incisions in the prostate gland to relieve urinary obstruction caused by BPH. This procedure is typically performed using a cystoscope equipped with cutting instruments, allowing for targeted incisions that facilitate urine flow without the complete removal of prostate tissue.

Other procedures, such as prostatic urethral lift (PUL) and water vapor thermal therapy (WVT), provide additional minimally invasive options for managing BPH symptoms. PUL involves the placement of implants to lift and hold the enlarged prostate tissue away from the urethra, while WVT utilizes steam to reduce prostate tissue volume and improve urine flow.

Global Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market, Segmentation by Geography

In this report, the Global Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Share (%), by Geographical Region, 2021

Europe is another prominent market for BPH treatment devices, characterized by well-established healthcare systems and increasing healthcare expenditure. Countries such as Germany, the UK, and France lead in adopting minimally invasive BPH treatment technologies, including laser therapies and robotic-assisted surgeries. The region's stringent regulatory framework ensures high standards of product safety and efficacy, driving demand for advanced BPH treatment solutions.

Asia-Pacific is witnessing rapid market growth due to rising awareness of BPH, expanding geriatric population, and improving healthcare infrastructure in countries like China, Japan, and India. Increasing disposable incomes and healthcare investments contribute to the adoption of BPH treatment devices, particularly laser technologies and minimally invasive procedures, catering to the region's diverse patient population and healthcare needs.

Latin America and Middle East & Africa are emerging markets for BPH treatment devices, fueled by improving healthcare access, growing prevalence of BPH, and rising healthcare investments. These regions present opportunities for market expansion, driven by efforts to enhance healthcare infrastructure and address unmet medical needs in BPH management. Government initiatives and partnerships with international healthcare providers play pivotal roles in advancing BPH treatment options and market penetration in these regions.

This report provides an in depth analysis of various factors that impact the dynamics of Global Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers :

• Aging population
• Increasing prevalence of BPH
• Technological advancements in treatment devices

• Minimally invasive procedures - Minimally invasive procedures have revolutionized the treatment landscape for benign prostatic hyperplasia (BPH), offering patients effective symptom relief with fewer complications and faster recovery times compared to traditional surgical approaches. These procedures leverage advanced medical technologies to target and treat enlarged prostate tissue while preserving surrounding healthy tissue, thereby improving overall patient outcomes and quality of life.

  One of the most widely adopted minimally invasive procedures for BPH is Transurethral Resection of the Prostate (TURP), which involves the use of a resectoscope to remove obstructing prostate tissue. TURP is known for its efficacy in reducing urinary symptoms such as hesitancy, urgency, and incomplete bladder emptying. While considered a gold standard in BPH treatment, newer minimally invasive alternatives have gained popularity due to advancements in technology and patient preference for less invasive interventions.

  Laser therapies have emerged as prominent alternatives to TURP, offering precise tissue ablation and vaporization without the need for surgical incisions. Techniques such as GreenLight laser therapy and Holmium laser enucleation of the prostate (HoLEP) utilize laser energy to reduce prostate tissue volume, improving urinary flow and minimizing post-operative complications like bleeding. Laser therapies are favored for their shorter hospital stays, quicker recovery times, and reduced risk of sexual side effects compared to traditional surgery.

  Minimally invasive procedures for BPH treatment represent a significant advancement in urological care, catering to patient preferences for less invasive interventions and shorter recovery times. As technology continues to evolve and clinical outcomes improve, these procedures are expected to play an increasingly pivotal role in managing BPH globally, enhancing patient quality of life and reducing healthcare costs associated with traditional surgical approaches.

Restraints :

• High treatment costs
• Limited access to advanced medical facilities in certain regions
• Regulatory hurdles and approval processes for new devices

• Patient reluctance towards surgical interventions - Patient reluctance towards surgical interventions for benign prostatic hyperplasia (BPH) stems from several factors that influence treatment decision-making and patient outcomes. Surgical procedures, such as Transurethral Resection of the Prostate (TURP) or open prostatectomy, are effective in reducing symptoms but are often associated with perceived risks, recovery challenges, and potential impact on quality of life.

  One of the primary concerns for patients considering surgical interventions is the risk of complications. While modern surgical techniques have significantly reduced the incidence of complications such as bleeding, infection, and urinary incontinence, these risks can still be a deterrent for patients, especially those with underlying health conditions or advanced age.

  Recovery time and post-operative discomfort are also significant factors contributing to patient reluctance. Traditional surgical procedures may require hospitalization and entail a longer recovery period compared to minimally invasive techniques. Patients may anticipate prolonged catheterization, temporary urinary symptoms, and restrictions on daily activities, impacting their overall quality of life during the recovery phase.

  Additionally, Anesthesia-related concerns and the general discomfort associated with undergoing surgery contribute to patient apprehension. Some patients may have anxiety or fear related to anesthesia administration, post-operative pain management, and the overall surgical experience, influencing their decision-making process and treatment preference.

Opportunities :

• Expansion into emerging markets with growing healthcare infrastructure
• Development of innovative and minimally invasive treatment technologies
• Increasing adoption of outpatient procedures

• Rising demand for non-surgical treatment options - The rising demand for non-surgical treatment options for benign prostatic hyperplasia (BPH) reflects a shift towards minimally invasive interventions that offer effective symptom relief while minimizing the risks and recovery associated with traditional surgical procedures. Several factors contribute to this trend and underscore the increasing preference among patients and healthcare providers for non-surgical alternatives.

  Non-surgical treatments are often performed in outpatient settings, allowing patients to return home shortly after the procedure and resume normal activities sooner. This reduces the disruption to daily life and may be particularly appealing to patients who prefer a less invasive treatment experience with minimal hospitalization and recovery time.

  Increasingly, patients are actively seeking treatment options that offer effective symptom relief with fewer procedural risks and discomfort. Non-surgical treatments align with patient preferences for less invasive interventions that minimize the impact on overall health and well-being, promoting greater treatment compliance and satisfaction.

  Ongoing advancements in medical technology and clinical research have expanded the range of non-surgical options available for BPH treatment. These innovations continue to improve treatment efficacy, safety profiles, and patient outcomes, further supporting the growing demand for non-surgical alternatives in urological care.

Key players in Global Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market include :

• Karl Storz
• Lumenis
• Olympus
• Urologix
• Boston scientific Inc.

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis